Welcome to International Network for Natural Sciences | INNSpub

Efficacy of Sofosbuvir plus Ribavirin in treatment of cirrhotic patients with HCV genotype 2 and 3 infections in Pakistan

Research Paper | February 1, 2020

| Download 9

Aminullah, Irshad ur Rehman, Saeed Ahmad, Jamshaid Ahmad, Bashir Ahmad

Key Words:

Int. J. Biosci.16( 2), 143-153, February 2020

DOI: http://dx.doi.org/10.12692/ijb/16.2.143-153


IJB 2020 [Generate Certificate]


Hepatitis C virus (HCV) is one of the leading causes of liver cirrhosis. Adjunctive therapy of ribavirin and interferon is commonly used against HCV infection, but it has wide diverse side effects. Currently, there is an urgent need for the development of new alternate therapy for combating HCV infections. This study is aimed to assess the efficacy of sofosbuvir plus ribavirin treatment in HCV cirrhotic patients (genotypes 2 and 3), viral drug response and to prevent progression of cirrhosis by eradication of HCV. Sample of 62 HCV cirrhotic patients were collected from the Gastroenterology ward of local hospital. Multiplex and real-time PCR were used to determine the genotypes and viral load respectively. The subjects were divided into two groups; A and B; A (HCV genotype 2), B (HCV genotype 3) infections. Group A and B received sofosbuvir (400 mg daily) plus ribavirin (200 mg twice daily) for 3 and 6 months respectively. The blood samples were further analyzed for the presence of viral RNA.Sustained Virologic Response (SVR) was shown by 88.70% of HCV cirrhotic patients. Group A patients (genotype 2) disclosed a good response to sofosbuvir (SVR 92%) as compared to group B (genotype 3; 88%). The SVR of group B patients was 70% and 88% after 12 and 24 weeks of treatment respectively. Sofosbuvir plus ribavirin may be prescribed for the treatment of HCV genotype 2 (3-months) and genotype 3 patients (6-months) with liver cirrhosis.


Copyright © 2020
By Authors and International Network for
Natural Sciences (INNSPUB)
This article is published under the terms of the Creative
Commons Attribution Liscense 4.0

Efficacy of Sofosbuvir plus Ribavirin in treatment of cirrhotic patients with HCV genotype 2 and 3 infections in Pakistan

Afridi SQ, Ali MM, Awan F, Zahid MN, Afridi IQ, Afridi SQ, Yaqub T. 2014. Molecular epidemiology and viral load of HCV in different regions of Punjab, Pakistan. Virology journal 11(1), 24.

Afridi SQ, Zahid MN, Shabbir MZ, Hussain Z, Mukhtar N, Tipu MY, Akhtar F, Yaqub T. 2013. Prevalence of HCV genotypes in district Mardan. Virology journal 10(1), 90.

Afsheen Z, Ahmad B, Bashir S. 2017. Hospital-visiting pregnant women signal an increased spread of hepatitis C infection in Khyber Pakhtunkhwa region of Pakistan. Virology Journal 14(1), 195.

Akahane T, Kurosaki M, Itakura J, Tsuji K, Joko K, Kimura H, Nasu A, Ogawa C, Kojima Y, Hasebe C, Wada S. 2019. Real‐world efficacy and safety of sofosbuvir+ ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group. Hepatology Research 49(3), 264-70.

Akhtar N, Bilal M, Rizwan M, Khan MA, Khan A. 2015. Genotypes of hepatitis C virus in relapsed and non-respondent patients and their response to anti-viral therapy in district Mardan, Khyber Pakhtunkhwa, Pakistan. Asian Pacific Journal of Cancer Prevention16, 1037-1040.

Al Kanaani Z, Mahmud S, Kouyoumjian SP, Abu-Raddad LJ. 2018. The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses. Royal Society open science 5(4), 180257.

Bethea ED, Chen Q, Hur C, Chung RT, Chhatwal J. 2018. Should we treat acute hepatitis C? A decision and cost‐effectiveness analysis. Hepatology67(3), 837-846.

Bourlière M, Khaloun A, WartelleBladou C. 2011. Chronic hepatitis C: treatments of the future. Clin Res Hepatol Gastroenterology 35(2), 84-95.

Butt S, Idrees M, Akbar H, ur Rehman I, Awan Z, Afzal S, Hussain A, Shahid M, Manzoor S, Rafique S. 2010. The changing epidemiology pattern and frequency distribution of hepatitis C virus in Pakistan. Infection, Genetics and Evolution 10(5), 595-600.

Chung RT. 2012. A watershed moment in the treatment of hepatitis C. New England Journal Medicine 366, 273-5.

Das BR, Kundu B, Khandapkar R, Sahni S. 2002 Geographical distribution of hepatitis C virus genotypes in India. Indian Journal of Pathology & Microbiology 45, 323–8.

European Association for the Study of the Liver Recommendations on treatment of hepatitis C. 2014. http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C.pdf

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales Jr FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 347(13), 975-82.

Gayam V, Mandal AK, Khalid M, Mukhtar O, Gill A, Garlapati P, Khalid M, Mansour M. 2018. Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting. International journal of hepatology 2018.

Hammer GD, McPhee SJ. Pathophysiology of Disease: An Introduction to Clinical Medicine 7/E. McGraw Hill Professional 2014.

Idrees M, Lal A, Malik FA, Hussain A, ur Rehman I, Akbar H, Butt S, Ali M, Ali L. 2011. Occult hepatitis C virus infection and associated predictive factors: the Pakistan experience. Infection, Genetics and Evolution 11(2), 442-5.

Iredale JP. 2003. Cirrhosis: new research provides a basis for rational and targeted treatments. Bmj 327(7407), 143-7.

Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E. 2013. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. New England Journal of Medicine 368(20), 1867-77.

Kanda T, Yokosuka O, Omata M. 2013. Hepatitis C Virus and Hepatocellular Carcinoma. Biology 2, 304-16.

Kemp L, Clare KE, Brennan PN, Dillon JF. 2018. New horizons in hepatitis B and C in the older adult. Age and ageing48(1), 32-37.

Khan MSA, Khalid M, Ayub N, Javed M. 2014. Seroprevalence and risk factors of Hepatitis C virus (HCV) in Mardan, N.W.F.P. Rawal Med J 29, 57-60.

Lam AM, Murakami E, Espiritu C, Steuer HM, Niu C, Keilman M, Bao H, Zennou V, Bourne N, Julander JG, Morrey JD. 2010.PSI-7851, a pronucleotide of β-D-2′-deoxy-2′-fluoro-2′-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrobial agents and chemotherapy 54(8), 3187-96.

Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM. 2013. Sofosbuvir for previously untreated chronic hepatitis C infection. New England Journal of Medicine 368(20), 1878-87.

McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine 339(21), 1485-92.

Mukhtar NA, Ness EM, Jhaveri M, Fix OK, Hart M, Dale C, Kowdley KV. (2019). Epidemiologic features of a large hepatitis C cohort evaluated in a major health system in the western United States. Annals of hepatology18(2), 360-365.

Munaf A, Memon MS, Kumar P, Ahmed S, Kumar MB. 2014. Comparison of viral hepatitis-associated hepatocellular carcinoma due to HBV and HCV – cohort from liver clinics in Pakistan. Asian Pacific Journal of Cancer Prevention 15, 7563-7.

Narahari S, Juwle A, Basak S, Saranath D. 2009. Prevalence and geographic distribution of hepatitis C virus genotypes in Indian patient cohort. Infection, Genetics and Evolution 9, 643–5.

Puche JE, Saiman Y, Friedman, SL. 2013. Hepatic stellate cells and liver fibrosis. Comprehensive Physiology 3(4), 1473-92.

Rockstroh J, Grint D, Boesecke C, Soriano V, Lundgren J, Monforte AD, Mitsura VM, Kirk O, Mocroft A, Peters L. 2012. Increases in acute hepatitis C (HCV) incidence across Europe: which regions and patient groups are affected? In11th International Congress on Drug Therapy in HIV Infection (HIV11) 1, 11-15.

Rockstroh JK. Summary from EASL 2013 for hepatitis C – new HCV DAAs on their way soon: what do the phase III studies tell us? Available from: [Last accessed on March 2014]. http://natap.org/2013/EASL/EASL_106.htm

Schmidt-MD, Houlihan D, McCormick A. 2014. From the CUPIC study: Great times are not coming (?). Journal of Hepatology 60(4), 899-900.

Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, Reddy PG, Ross BS, Wang P, Zhang HR, Bansal S. 2010. Discovery of a β-d-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. Journal of medicinal chemistry 53(19), 7202-18.

Soriano V, Vispo E, Poveda E, Labarga P, Barreiro P. 2012. Treatment failure with new hepatitis C drugs. Expert opinion on pharmacotherapy 13, 313-23.

Tang H, Grise H. 2009. Cellular and molecular biology of HCV infection and hepatitis. Clinical Science 117, 49-65.

Tokita H, Shrestha SM, Okamoto H, Sakamoto M, Horikita M, Iizuka H, Shrestha S, Miyakawa Y, Mayumi M. 1994.  Hepatitis C virus variants from Nepal with novel genotypes and their classification into the third major group. Journal of general virology 75(4), 931-6.

Tucker M. 6th December 2013. FDA Approves ‘Game Changer’Hepatitis-C Drug Sofosbuvir. Medscape.

Wang LS, D’souza LS, Jacobson IM. 2016. Hepatitis C—A clinical review. Journal of Medical Virology 88(11), 1844-1855.

World Health Organisation Report 18th July, 2018. http://www.who.int/news-room/fact-sheets/detail/hepatitis-c.

Wyles DL. 2012. Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection. Topics in antiviral medicine 20, 139-45.